Drug intelligence / Profile preview

vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus

Development stage
Phase 3
Lead developer
SillaJen
Modality
Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

A **recombinant vaccinia virus** genetically engineered to express **granulocyte-macrophage colony-stimulating factor (GM-CSF)**. This oncolytic virus both lyses tumor cells and delivers **GM-CSF** to locally stimulate the immune response, enhancing recruitment, maturation, and activation of dendritic cells, macrophages, and neutrophils. The immune stimulation supports antigen presentation and cytotoxic T cell responses against tumors. It has shown antitumor efficacy in experimental models and limited trials, notably in melanoma and other solid tumors[2][3][4]. Common features include viral deletions (e.g., thymidine kinase gene) to restrict replication to tumor cells, and expression of human GM-CSF via a secretory leader sequence. Primary indications under investigation are melanoma, breast cancer, drug-resistant lymphosarcoma, and other advanced solid tumors.

Brand names
Pexa-Vec
Other names
recombinant vaccinia virus expressing GM-CSFGM-CSF-armed vaccinia virusGM-CSF-expressing vaccinia virusVV-GMCSF
02

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call